来那度胺通过维生素D通路增强MOR202依赖性巨噬细胞介导的效应功能
本研究探讨维生素D通路对骨髓瘤相关巨噬细胞(MAMs)杀伤活性的调节。MAMs的维生素D通路存在缺陷,来那度胺可在体外恢复其杀伤活性;含IMiD治疗可改善MAMs经MOR202介导的细胞毒活性,补充维生素D可进一步增强该活性。
要点
- MAMs的维生素D通路存在缺陷,CYP27B1表达降低且杀伤活性有限。
- 来那度胺可在体外恢复MAMs的杀伤活性。
- 含IMiD治疗可改善MAMs经MOR202介导的细胞毒活性,补充维生素D可进一步增强。
核心结论
- 维生素D对MAMs的效应功能起关键作用,在IMiD联合试验中补充维生素D可能进一步提高抗CD38抗体(如MOR202)的疗效,尚需临床研究验证。
研究设计与样本
- 体外研究结合MM患者MAMs的离体分析,评估维生素D通路调节对MAMs杀伤活性的影响。
主要发现
- MAMs显示维生素D通路缺陷,CYP27B1表达水平降低且杀伤活性有限,来那度胺可在体外恢复其杀伤活性。
- 含IMiD治疗期间MM患者MAMs的维生素D通路可恢复,表现为MAMs对原代MM细胞的MOR202介导细胞毒活性改善。
- 离体细胞毒活性可通过补充维生素D进一步增强。
临床怎么用
- 作者认为维生素D对MAMs效应功能起关键作用,在IMiD联合试验中补充维生素D可能进一步提高抗CD38抗体(如MOR202)的疗效,尚需临床研究验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Macrophages are key mediators of the therapeutic effects exerted by monoclonal antibodies, such as the anti-CD38 antibody MOR202, currently introduced in multiple myeloma (MM) therapy. Therefore, it is important to understand how antibody-mediated effector functions of myeloma-associated macrophages (MAMs) are regulated. Here, we focused on the effects of vitamin D, a known regulator of macrophage effector functions. Consequently, it was the aim of this study to assess whether modulation of the vitamin D pathway alters the tumoricidal activity of MAMs. Here, we demonstrate that MAMs display a defective vitamin D pathway with reduced expression level of CYP27B1 and limited tumoricidal activity which can be restored by the IMiD lenalidomide in vitro. Furthermore, our data indicate that the vitamin D pathway of MAMs from MM patients does recover during an IMiD-containing therapy shown by an improved MOR202-mediated cytotoxic activity of these MAMs against primary MM cells ex vivo. Here, the ex vivo cytotoxic activity could be further enhanced by vitamin D supplementation. These data suggest that vitamin D holds a key role for the effector functions of MAMs and that vitamin D supplementation in IMiD combination trials could further increase the therapeutic efficacy of anti-CD38 antibodies such as MOR202, which remains to be investigated in clinical studies.
引用
- Busch L, Mougiakakos D, Büttner-Herold M, et al. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia. 2018. PMID: 29654274. doi:10.1038/s41375-018-0114-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。